Pre-surgery chemotherapy and antibodies for HER2 breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and age 18 to 70.
- You have newly diagnosed invasive breast cancer and have not had breast-cancer treatment yet.
- Your tumor is HER2-positive (from tumor testing like IHC or biopsy test results).
- Your cancer is operable (not spread to distant organs) and is larger than 2 cm.
- Your biopsy shows cancer in nearby lymph nodes within the last 28 days before randomization.
- Your heart function is strong enough (left-heart pumping LVEF at least 55%) and heart blood tests (BNP/NT-proBNP and troponin) are normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This study tests two chemotherapy drugs, lobaplatin and carboplatin, given before surgery for HER2 positive breast cancer. The goal is to see if they are safe and help shrink the tumor before it is removed.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.